Analyzing CannTrust (CTST) & Its Rivals

Share on StockTwits

CannTrust (NYSE: CTST) is one of 546 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare CannTrust to similar companies based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, valuation, profitability and risk.

Valuation & Earnings

This table compares CannTrust and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CannTrust $35.22 million -$10.46 million -62.45
CannTrust Competitors $2.17 billion $229.91 million -3.77

CannTrust’s peers have higher revenue and earnings than CannTrust. CannTrust is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares CannTrust and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CannTrust -28.09% -7.34% -6.31%
CannTrust Competitors -1,776.08% -105.48% -28.48%

Volatility & Risk

CannTrust has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500. Comparatively, CannTrust’s peers have a beta of 1.39, indicating that their average stock price is 39% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for CannTrust and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CannTrust 0 1 0 0 2.00
CannTrust Competitors 4499 12939 27592 991 2.54

CannTrust presently has a consensus price target of C$14.50, indicating a potential upside of 111.06%. As a group, “Pharmaceutical preparations” companies have a potential upside of 52.46%. Given CannTrust’s higher possible upside, research analysts clearly believe CannTrust is more favorable than its peers.

Institutional & Insider Ownership

0.1% of CannTrust shares are held by institutional investors. Comparatively, 46.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

CannTrust peers beat CannTrust on 8 of the 13 factors compared.

CannTrust Company Profile

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Comparing Q.E.P.  & TOUGHBUILT INDU/SH
Comparing Q.E.P. & TOUGHBUILT INDU/SH
Head-To-Head Analysis: BERKELEY GRP HO/ADR  & PANALPINA WELTT/ADR
Head-To-Head Analysis: BERKELEY GRP HO/ADR & PANALPINA WELTT/ADR
Grafton Group plc  Given Consensus Rating of “Buy” by Brokerages
Grafton Group plc Given Consensus Rating of “Buy” by Brokerages
Zacks: Analysts Anticipate Schneider National Inc  Will Announce Earnings of $0.31 Per Share
Zacks: Analysts Anticipate Schneider National Inc Will Announce Earnings of $0.31 Per Share
eXPerience Chain  Market Cap Reaches $1.98 Million
eXPerience Chain Market Cap Reaches $1.98 Million
win.win Reaches Market Capitalization of $701,282.00
win.win Reaches Market Capitalization of $701,282.00


 
© 2006-2019 Zolmax.